Table 2.
Name | FSH |
LH |
FSH versus LH |
|||||
---|---|---|---|---|---|---|---|---|
HCF | HKC | HCF versus HKC | HCF | HKC | HCF versus HKC | HCF | HKC | |
GnRHR | ||||||||
AR | Up ↑ | Down ↓ | ||||||
PR | Up ↑ | Down ↓ | ||||||
ERβ | Up ↑ | Up ↑ | Up ↑ | |||||
ERα | Down ↓ | Down ↓ | ||||||
α-SMA | Down ↓ | Down ↓ | Down ↓ | |||||
EDA-Fn | Down ↓ | Down ↓ | ||||||
Keratocan | Down ↓ | Up ↑ | Down ↓ | Up ↑ | ||||
Lumican | Down ↓ | Down ↓ | Down ↓ | Down ↓ | ||||
CYP3A4 | ||||||||
PKA | Down ↓ | |||||||
CRH | ||||||||
GPER | Up ↑ | Up ↑ | Up ↑ | |||||
cAMP | ||||||||
CREB | Up ↑ | |||||||
ERK 1/2 | ||||||||
pan-AKT | Up ↑ | Down ↓ | ||||||
JNK | Down ↓ |
AR, androgen receptor; CREB, cAMP response element–binding protein; CRH, corticotropin-releasing hormone; CYP, cytochrome P450; EDA-Fn, fibronectin-containing extra domain A; ER, estrogen receptor; GnRHR, gonadotropin-releasing hormone receptor; GPER, G protein–coupled estrogen receptor; JNK, c-Jun N-terminal kinase; pan-AKT, protein kinase B with potential antineoplastic activity; PKA, protein kinase A; PR, progesterone receptor; SMA, smooth muscle actin.